Dr. Jan M. Lundberg, former head of R&D at AstraZeneca and Eli Lilly has joined Betagenon’s board of directors
Dr. Jan M Lundberg brings extensive industrial competence to Betagenon"Jan’s executive industrial experience as head of R&D at two major pharmaceutical companies, and his involvement the discovery, development and approval of more than 20 products makes his experience and competence invaluable to Betagenon. As a member of the board of directors and as an investor, Jan will add significant strategic competence to the further clinical development and out-licensing of our First-in-Class PAN-AMPK activator O304." said Thomas Edlund, CEO of Betagenon AB. At Eli Lilly Dr. Lundberg, as head